Skip to main content

Black Diamond Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

BDTX$1.60-14.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

(in thousands, except share and per share data)

Three Months EndedJune 30,Six Months EndedJune 30,
2026202520262025
License revenue$—$—$—$70,000
Operating expenses:
Research and development$7,393$9,319$14,396$19,825
General and administrative4,6644,1018,9209,065
Total operating expenses12,05713,42023,31628,890
Income (loss) from operations(12,057)(13,420)(23,316)41,110
Other income (expense):
Interest income9221,1181,9451,713
Other income (expense)1,2301,7412,4303,158
Total other income (expense), net2,1522,8594,3754,871
Net income (loss)$(9,905)$(10,561)$(18,941)$45,981
Net income (loss) per share - basic$(0.17)$(0.19)$(0.33)$0.81
Net income (loss) per share - diluted$(0.17)$(0.19)$(0.33)$0.80
Weighted average common shares outstanding - basic57,367,28356,803,45057,300,71856,734,010
Weighted average common shares outstanding - diluted57,367,28356,803,45057,300,71857,474,118
Comprehensive income (loss):
Net income (loss)$(9,905)$(10,561)$(18,941)$45,981
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net(32)(6)(169)(49)
Comprehensive income (loss)$(9,937)$(10,567)$(19,110)$45,932
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.